B
Beam Therapeutics
developing precision genetic medicines for serious diseases
At a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Beam Therapeutics in the Cambridge ecosystem
The Beam Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later10 investors entered at this stage
Cormorant Asset Management- AVAltitude Life Science Ventures
F-Prime- HUHarvard University
- OFOmega Funds
- DRDreamers
- RGRedmile Group
- DHDHVC
ARCH Venture Partners
Eight Roads Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former Beam Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
PAPairwiseEst. 2017
David LiuUnited States
PMPrime MedicineEst. 2019
VTVerve TherapeuticsEst. 2018
Keith JoungUnited States
OTOrbital TherapeuticsEst. 2022Patents
90 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Beam Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Beam's base-edited cell therapy risto-cel hits primary endpoint in pivotal sickle cell trial
ARK pours $17M into Cerebras, exits AMD and Palantir
